IDWeek 2012: HIV

A pilot study presented at IDWeek 2012 to assess durability of HIV-1 virologic suppression in subjects who switched from HAART regimen to lopinavir/ritonavir monotherapy failed to maintain viral suppression in a sufficient number of subjects to continue the study, investigators reported.

A study reported at IDWeek 2012 comparing the efficacy of different statins when co-administered with highly active antiretroviral therapy in patients with HIV found no significant difference in LDL reduction.

A study of patients with chronic hepatitis C and a history of hepatocellular carcinoma treated with pegylated interferon alpha-2b plus ribavirin showed a high risk of recurrence, according to data presented at IDWeek 2012.

The antiretroviral combination known as “the Quad” demonstrated comparable efficacy and favorable tolerability to Atripla in adherent treatment-naïve patients with HIV infection, according to a a study presented at IDWeek 2012.

Virologic failure of second-line combination ART was less likely if patients were switched with an HIV RNA viral load (VL) <400c/mL, according to a study presented at IDWeek 2012.

The pharmacokinetics across combinations of concomitant telaprevir and efavirenz or atazanavir/ritonavir-based regiments in hepatitis C (HCV)/HIV co-infected patients were comparable and consistent with those observed historically in HCV mono-infected patients, according to Varun Garg, PhD, from Vertex Pharmaceuticals, Inc., Cambridge, MA, at IDWeek 2012.

Efavirenz-, atazanavir + ritonavir-, and raltegravir-containing regimens are compatible for use with direct acting antivirals, stated Sonia Vibhakar, PharmD, from The Ruth M. Rothstein CORE Center, Chicago, IL, and colleagues, at IDWeek 2012.